{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:42:56Z","timestamp":1786164176067,"version":"build-2736575974"},"reference-count":38,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7870-26","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T22:10:12Z","timestamp":1786140612000},"source":"Crossref","is-referenced-by-count":0,"title":["<i>TP<\/i>53-mutated Therapy-related Leukemia with the Der(5;17)(p10;q10) Chromosomal Abnormality Following Chemotherapy for Acute Promyelocytic Leukemia Bridged to Allogeneic Hematopoietic Stem Cell Transplantation Using CPX-351"],"prefix":"10.2169","author":[{"given":"Aya","family":"Kamiya","sequence":"first","affiliation":[{"name":"Department of Hematology, Tottori Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tottori Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Omura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tottori Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tottori Prefectural Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","first-page":"937","volume":"84","author":"G Leone","year":"1999","unstructured":"1. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica 84: 937-945, 1999.","journal-title":"Haematologica","ISSN":"https:\/\/id.crossref.org\/issn\/0390-6078","issn-type":"print"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Mauritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 16: 2366-2378, 2002.","DOI":"10.1038\/sj.leu.2402713"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Green SD, Wang ES. How I treat secondary acute myeloid leukemia. Blood 145: 1260-1272, 2025.","DOI":"10.1182\/blood.2024024011"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sperotto A, Stanghellini MTL, Peccatori J, et al. CPX-351 and allogeneic stem cell transplant for a therapy-related acute myeloid leukemia that developed after treatment of acute promyelocytic leukemia: a case report and review of the literature. Front Oncol 13: 1291457, 2024.","DOI":"10.3389\/fonc.2023.1291457"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Latagliata R, Petti MC, Fenu S, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 99: 822-824, 2002.","DOI":"10.1182\/blood.V99.3.822"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Lobe I, Rigal-Huguet F, Vekhoff A, et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia 17: 1600-1604, 2003.","DOI":"10.1038\/sj.leu.2403034"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Montesinos P, Gonz\u00e1lez JD, Gonz\u00e1lez J, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. J Clin Oncol 28: 3872-3879, 2010.","DOI":"10.1200\/JCO.2010.29.2268"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Russell N, Burnett A, Hills R, et al. Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. Blood 132: 1452-1454, 2018.","DOI":"10.1182\/blood-2018-05-851824"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takase K, Kamimura T, Kuriyama T, et al. Frontline ATRA-ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG-APL2017 Trial. Cancer Sci 117: 1117-1123, 2026.","DOI":"10.1111\/cas.70328"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 36: 2684-2692, 2018.","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 8: e481-e491, 2021.","DOI":"10.1016\/S2352-3026(21)00134-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Molica M, Giannarelli D, De Fazio L, Rossi M, Perrone S. CPX-351 in secondary\/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3200 patients. Haematologica 2025.","DOI":"10.3324\/haematol.2025.300076"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rautenberg C, Middeke JM, R\u00f6llig C, et al. Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients. Blood Cancer J 15: 60, 2025.","DOI":"10.1038\/s41408-025-01274-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gaut D, Sasine J, Schiller G. Secondary clonal hematologic neoplasia following successful therapy for acute promyelocytic leukemia (APL): A report of two cases and review of the literature. Leuk Res Rep 9: 65-71, 2018.","DOI":"10.1016\/j.lrr.2018.04.005"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Miyazaki H, Ino T, Sobue R, et al. Translocation (3;21)(q26;q22) in treatment-related acute leukemia secondary to acute promyelocytic leukemia. Cancer Genet Cytogenet 74: 84-86, 1994.","DOI":"10.1016\/0165-4608(94)90002-7"},{"key":"16","unstructured":"16. Todisco E, Testi AM, Avvisati G, et al. Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia. Leukemia 9: 1583-1585, 1995."},{"key":"17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood.V90.3.1321","volume":"90","author":"G Meloni","year":"1997","unstructured":"17. Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML\/RAR alpha fusion gene. Blood 90: 1321-1325, 1997.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Felice MS, Rossi J, Gallego M, et al. Acute trilineage leukemia with monosomy of chromosome 7 following an acute promyelocytic leukemia. Leuk Lymphoma 34: 409-413, 1999.","DOI":"10.3109\/10428199909050968"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Annunziata M, Palmieri S, Pocali B, et al. Therapy-related acute myeloid leukemia with t(9;11)(p12;q23) in a patient treated for acute promyelocytic leukemia. Hematol J 4: 289-291, 2003.","DOI":"10.1038\/sj.thj.6200256"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lee GY, Christina S, Tien SL, et al. Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia. Cancer Genet Cytogenet 159: 129-136, 2005.","DOI":"10.1016\/j.cancergencyto.2004.09.019"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Bao L, Lu X, Lai Y, et al. Therapy-related acute myeloid leukemia after successful therapy for acute promyelocytic leukemia with t(15;17): A case report and literature review. Leuk Res 33: e64-68, 2009.","DOI":"10.1016\/j.leukres.2009.01.043"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Batzios C, Hayes LA, He SZ, et al. Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia. Am J Hematol 84: 715-719, 2009.","DOI":"10.1002\/ajh.21528"},{"key":"23","unstructured":"23. Betancourt-Garc\u00eda RD, Castro J, Fern\u00e1ndez AC, L\u00f3pez-Enr\u00edquez A, Fradera J, Pacheco E. Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature. P R Health Sci J 28: 146-150, 2009."},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Imagawa J, Harada Y, Shimomura T, et al. Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia. Blood 116: 6018-6022, 2010.","DOI":"10.1182\/blood-2010-06-289389"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kelemen K, Kovacsovics T, Braziel R, Corless C, Beadling C, Fan G. RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma 53: 999-1002, 2012.","DOI":"10.3109\/10428194.2011.634047"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ojeda-Uribe M, Schneider A, Luquet I, et al. Therapy-related acute myeloid leukemia (t-AML) with poor-risk cytogenetics in two patients with persistent molecular complete remission of acute promyelocytic leukemia. Eur J Haematol 89: 267-272, 2012.","DOI":"10.1111\/j.1600-0609.2012.01805.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Sahoo RK, Kumar L, Kumar R, Sharma A. Acute promyelocytic leukemia relapsing into acute myeloid leukemia-M2 with normal cytogenetics. Indian J Med Paediatr Oncol 34: 327-329, 2013.","DOI":"10.4103\/0971-5851.125261"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Park SH, Chi HS, Cho YU, Jang S, Park CJ, Lee JH. A case of therapy-related acute myeloid leukemia with a normal karyotype after sustained molecular complete remission of acute promyelocytic leukemia. Ann Lab Med 34: 68-70, 2014.","DOI":"10.3343\/alm.2014.34.1.68"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Wang T, Jacoby MA, Duncavage EJ, et al. Exome analysis of treatment-related AML after APL suggests secondary evolution. Br J Haematol 185: 984-987, 2019.","DOI":"10.1111\/bjh.15681"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Hong M, Hao S, Patel KP, et al. Whole-arm translocation of der (5;17) (p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. Cancer Genet 209: 205-214, 2016.","DOI":"10.1016\/j.cancergen.2016.04.001"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Shimony S, Murdock HM, Keating J, et al. CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial. Blood Adv 10: 2854-2864, 2026.","DOI":"10.1182\/bloodadvances.2025019378"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Shimony S, Garcia JS, Keating J, et al. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38: 1494-1500, 2024.","DOI":"10.1038\/s41375-024-02230-w"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 139: 2347-2354, 2022.","DOI":"10.1182\/blood.2021014472"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Makishima H, Mikasa T, Isogaya K, et al. Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1\/2 study of NS-87\/CPX-351. Int J Hematol 122: 57-65, 2025.","DOI":"10.1007\/s12185-025-03956-8"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Guolo F, Fianchi L, Minetto P, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J 10: 96, 2020.","DOI":"10.1038\/s41408-020-00361-8"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 29: 979-985, 2011.","DOI":"10.1200\/JCO.2010.30.5961"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Hosono N, Tomiyama Y, Emori N, Isogaya K, Yamauchi T. Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1\/2 study and global phase 3 study. Int J Hematol 122: 824-834, 2025.","DOI":"10.1007\/s12185-025-04047-4"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Guolo F, Fianchi L, Martelli MP, et al. Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation. Am J Hematol 100: 2293-2304, 2025.","DOI":"10.1002\/ajh.70083"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7870-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:06:37Z","timestamp":1786161997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7870-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":38,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7870-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7870-26"}}